Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted. Less than ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly ...

For further information on Bright Minds, investors should review the Company’s annual Form 40-F filing with the United States ...

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading ...

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to ...

The live and archived webcast for the Cantor event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and ...

Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.

BrightMinds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) today closed its recently announced ...